NATERA, INC. (NTRA): what the price assumes

In the published model solve dated 2026-Q2, anchored at $274.64, NATERA, INC. (NTRA) is priced for today's economics sustained for ~21.6 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/NTRA

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.9 years.

Reconcile: at the x-ray's 9.3% required return this reads ~15 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=5)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Natera runs a single business, the development and commercialization of DNA-based molecular testing services, and the molecular-residual-disease test Signatera now carries the story: Q1 2026 revenue reached $697 million, up 39% year over year, on the first quarter the company ever shipped more than one million units.
• The clearest risk is that the company still loses money: operating income ran roughly negative $324 million on a trailing basis, the share count has grown about 10% a year, and at about 14 times revenue the price needs the loss-making lab to become a structurally profitable one and stay growing for two decades.
• Watch reimbursement and pricing next: management lifted full-year gross-margin guidance toward 65% on improving Signatera realized prices, while a $292.5 million jury verdict in Guardant Health's false-advertising suit and a delayed CMS bundled-pricing rollout are the two near-term overhangs to track.

Bull Case

Genetic testing is a hard sector to value, because the economics arrive in the wrong order. A diagnostics company spends years building a test, securing reimbursement code by code, and proving clinical utility before a single dollar of profit shows up, which makes trailing earnings a poor read on what the business is becoming. Natera is the case study. The 10-K is blunt about what it is: "The Company operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology." That single segment is now scaling in a way the trailing operating loss does not capture.

The engine is Signatera, the tumor-informed test that looks for traces of a patient's specific cancer DNA in the blood after treatment. Volume is the tell. The company shipped more than one million total units in a single quarter for the first time in Q1 2026, and revenue grew 39% year over year to $697 million. The same print carried a gross-margin guide lifted toward 65% as realized prices on Signatera improved, the kind of move that matters far more than the trailing loss: in a testing business, the fixed lab cost is sunk, so each incremental dollar of better-priced volume drops a large share to gross profit. Management framed the exit average selling price near $1,275 and pointed to continued gains in payer coverage.

The competitive position is the second pillar, and it is unusually concentrated for a young category. Analysts now credit Natera with the leading share of the molecular-residual-disease market and more than a billion dollars of annualized Signatera revenue, the marks of a platform that has already scaled rather than one still hoping to. An NCCN guideline endorsement in late June added the kind of clinical validation that drives oncologist adoption, and the runway extends geographically: management noted Japan diagnoses roughly as many colorectal cancers as the United States, which a launch there could turn into a near-doubling of Signatera's colorectal volume opportunity. The 10-K's own competitive language is candid that this is a contest of standards and adoption, citing "price competition, aggressive marketing practices, evolving industry standards and changing customer preferences", and Natera is currently winning the adoption argument.

Bear Case

The advantage Natera is pressing, the tumor-informed approach that personalizes each Signatera test to a patient's own cancer, is also the place a bear watches for erosion, because rivals are racing to make the simpler tumor-naive approach good enough. Guardant Health markets Guardant Reveal as a blood-only test that skips the tumor-tissue step, and the rivalry has already turned legal: a federal jury awarded Guardant $292.5 million, including $175.5 million in punitive damages, finding Natera engaged in false advertising about Guardant's colorectal test. That is both a cash and a reputational liability, and it signals how contested the standard-of-care argument really is. The 10-K names the same pressure directly, warning of competition in women's health from "existing testing" and a market shaped by "evolving industry standards and changing customer preferences."

Underneath the competitive question sits the harder one: this is still a company that loses money. Trailing operating income ran about negative $324 million, and the price asks the reader to underwrite a turn that has not happened. At roughly 14 times revenue, the price implies the business eventually earns an operating margin near 15% and grows at close to its self-funding ceiling for about twenty years. Natera has shown it can grow at that pace recently; what it has not shown is that it can do so while turning a structural loss into a durable mid-teens profit, and history is unkind to that combination. Of comparable fast growers, only about 14% sustained this kind of pace even a decade.

The balance sheet does not bail out the thesis, it amplifies the demand on it. The company carries modest net debt of about $79 million against roughly $1 million of cash that the data treats as readily liquid, and the share count has grown about 10% a year, so existing holders are being diluted while the profit story is still a promise. Even the valuation methods agree on the direction: no family of method reaches the price. On assets, on peers, and on forward growth, the price sits well above where each lands, which means the bet is not that one conservative model is too cautious, it is that all of them are. The 10-K concedes the underlying volatility plainly, noting that "revenues, gross margin, net loss and cash flows, have varied and may continue to vary from period to period."

Valuation

Natera does not yet earn a normal operating profit, so the market is pricing the business against its sales rather than its earnings. At about 14 times revenue, the price embeds a specific and demanding bet: that the lab eventually settles at an operating margin near 15.5%, up from a trailing margin around negative 13%, and that it grows revenue near its self-funding ceiling for roughly twenty years to get there. The recent growth rate is within what the company has actually delivered; the stretch is in the duration, not the pace. The price is asking for two decades of compounding plus a full swing from loss to durable profit.

The disagreement among methods is unusually one-sided here. No family of valuation method reaches the price. The asset-based methods land far below it, the peer-multiple methods land well below, and even the forward-growth methods, which credit future expansion, do not get there. When every lens points the same way, the price is not a case of one conservative model lagging the story; it is a bet beyond what any standard frame supports. The reported gross margin in the trailing data sits around 39%, and the company's own filing sources the structural inputs the build rests on, describing its single molecular-testing segment and a revenue-recognition model tied to "performance obligations in the contracts" as they are satisfied. The forward path to a mid-teens operating margin depends on those contracts repricing upward, which is exactly the improvement management is now guiding toward, but the price has already credited the destination.

Solvency frames the downside. Net debt is small at about $79 million, but the company is not generating the operating profit that would normally service a balance sheet, and the share count has risen about 10% a year, so the funding of growth has fallen partly on existing holders. The recent move toward higher realized pricing is the single most important variable: if gross margin holds its new trajectory, the path to operating profitability shortens materially; if it stalls, the price has very little support beneath it.

Catalysts

The Q1 2026 print, reported in early May, was the operational high-water mark: revenue of $697 million, up 39% year over year, and the first quarter ever above one million total units. Management raised full-year guidance, lifting the revenue midpoint by roughly $120 million and the gross-margin target toward 65% as Signatera's realized average selling price moved toward an expected exit near $1,275. The net loss per share of $0.60 was modestly wider than the prior year and missed expectations, but the market focused on the volume and pricing momentum.

Reimbursement is the near-term swing factor. The CFO flagged a temporary step-up in days-sales-outstanding tied to implementation delays for new CMS bundled pricing, which pushed out some Signatera cash collections; that is a timing issue rather than a demand issue, but it is the kind of friction that can dent a quarter. On the clinical side, an NCCN guideline endorsement in late June gave Signatera fresh validation that tends to accelerate oncologist adoption, and analysts responded constructively: BTIG maintained Buy and raised its target to $275 on June 24, and RBC Capital reinstated coverage at Outperform with a $275 target on June 11, against a consensus near $229.

The longer arc is geographic and competitive. Management's framing of Japan, where colorectal cancer diagnoses run at a similar absolute level to the United States, points to a launch that could roughly double Signatera's colorectal volume opportunity over time. Against that, the $292.5 million Guardant Health verdict and the ongoing tumor-informed versus tumor-naive contest are the developments most likely to shape both the cash position and the standard-of-care narrative in the coming quarters.

Peer Cohorts (Per Segment, With Filing Citations)

Molecular testing services (consolidated) (reported)

• GH (GUARDANT HEALTH, INC.)
• FY2025 10-K: …and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue, subject to assessment of the risk of cumulative future revenue reversal. Biopharma and data Biopharma and data revenue includes amounts derived from the delivery of the…
• FY2025 10-K: …to increase market acceptance and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline. In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid…
• VCYT (VERACYTE, INC.)
• FY2025 10-K: …provider to handle insurance eligibility, prior authorization or claim submissions, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms or in a time frame acceptable to us. Any such delays or denials would have an adverse effect on our revenue and our…
• FY2025 10-K: …In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics, and Sonic Healthcare USA, with strong infrastructure to support the commercialization of diagnostic services. We also face potential competition from companies such as Thermo…
• LH (LABCORP HOLDINGS INC.)
• FY2025 10-K: …mix of testing services ordered, or a reduction in tests ordered, specimens submitted, or services requested by existing customers, and delays in payments from customers; 16. consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization,…
• FY2025 10-K: …alternatives, including value-based, bundled pay-for-performance, and other risk-sharing payment models. The growth of the managed care sector and consolidation of MCOs present various challenges and opportunities to Dx and other clinical laboratories. Dx's ability to attract and retain MCO customers has become even…
• DGX (QUEST DIAGNOSTICS INC)
• FY2025 10-K: …called "Medicare Advantage" programs. There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs. States also have mandated that Medicaid beneficiaries enroll in private managed care arrangements. We also provide additional services to and…
• FY2025 10-K: …costs but does not recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction of fee schedules payable to us, unilateral recoupment of amounts allegedly owed and competitive bidding. 39 Table of Contents (f) The impact upon our testing volume and collected…
• RDNT (RadNet, Inc.)
• FY2025 10-K: …Group has insignificant operating assets and liabilities, and de minimis equity. Substantially all cash flows of the Consolidated Medical Group after expenses, including professional salaries, are transferred to us. We consolidate 63 the revenue and expenses, assets and liabilities of the Consolidated Medical Group.…
• FY2025 10-K: …procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. Our Digital Health segment develops and…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.